Insider Selling in Emergent BioSolutions (EBS) Shares Continues

Wednesday, November 15, 2017 10:15 PM ET

Insider Selling in Emergent BioSolutions (EBS) Shares Continues

A substantial insider sale of the shares of Emergent BioSolutions was revealed in a form 4 document filed with the SEC today, showing — Fuad El-Hibri, 10% Owner, Director and Officer — sold 40,000 shares in the company having a market value of approximately $1,614,800. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the sale of 102,742 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 142,742 shares and have averaged 47,581 shares per transaction over this time period.

Emergent BioSolutions insider trading represents a level of buy/sell trades that is above for the 116 peer company average over the last 90-day period. The Pharmaceuticals peer group saw 81 buy/sell trades during this period for an average of 0.7 transactions per company. The number of shares per buy/sell trade for Emergent BioSolutions insiders was also higher. Within the peer group there were 794,799 shares purchased and 1,929,400 shares sold with company insiders selling 14,007 shares on average.

The data sourced in evaluating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.